Analysis: Does Kenvue (KVUE) Offer Value After Share Price Decline?

Kenvue (NYSE:KVUE) shares are currently trading at around $17.71, up 2.5% over the past week and 0.2% over the past month, but still down 14.7% over the past year. This raises the question of whether the stock presents a good buying opportunity or remains overvalued.

DCF Valuation

According to a discounted cash flow (DCF) model, the fair value of the stock may be higher than the current price. The model assumes a reasonable compound annual growth rate (CAGR) for revenue and free cash flow over the next five years, yielding a target price 10% to 20% above the current level.

Analyst Rationale

Analysts highlight that Kenvue, as a standalone consumer health company after its spin-off from Johnson & Johnson, has a strong portfolio of brands (e.g., Tylenol, Neutrogena) and stable margins. However, challenges include slowing growth in some markets and rising input costs.

Market Context

The stock's performance over the past year has been weak compared to the S&P 500, but it has shown some recovery in recent days. The average analyst price target is around $22, suggesting upside potential.

Conclusion

This article does not provide a buy or sell recommendation, but it indicates that the current valuation may be attractive based on DCF analysis. Investors should consider other factors such as competitive risks and valuation relative to peers.